Yaz "approvable" again
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering AG subsidiary Berlex continues to expect a first-quarter 2006 decision on the low-dose oral contraceptive Yaz (ethinyl estradiol 20 mcg/drospirenone 3 mg) following receipt of a second "approvable" letter Jan. 23. The NDA for the low-dose formulation of the firm's successful Yasmin product "is approvable pending [FDA's] review of recently submitted data and their satisfactory conclusion of its content," Berlex says. The approvable decision pertains primarily to additional data regarding patients with premenstrual dysphoric disorder. FDA extended Yaz' PDUFA date in December following submission of additional data (1Pharmaceutical Approvals Monthly December 2005, In Brief)...
You may also be interested in...
Berlex Yaz 90-day extension
Schering AG subsidiary Berlex expects approval of its low-dose Yasmin formulation Yaz (ethinyl estradiol 20 mcg/drospirenone 3 mg) in the first quarter of 2006, the firm says Dec. 9 after a 90-day extension of the oral contraceptive's PDUFA date. Berlex says that "shortly after" receipt of a November 2004 "approvable" letter, it submitted information on the formulation's dosing regimen (24 days of active pills, 4 days inactive) as well as data to support an additional indication for premenstrual dysphoric disorder...
Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: